Skip to main content
Premium Trial:

Request an Annual Quote

CML HealthCare Licenses Phenomenome Cancer Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CML HealthCare, a healthcare services provider that also provides lab testing services in Ontario, Canada, has licensed rights to commercialize Phenomenome Discoveries' blood tests to assess an individual's risk of cancer.

Saskatoon, Saskatchewan-based Phenomenome uses its metabolomic biomarker discovery platform and informatics research tools in developing its tests.

The firm's most advanced research program is in colorectal cancer. Phenomenome said that it has discovered high levels of over 30 novel metabolites in the blood of healthy individuals, which are deficient in the blood of up to 90 percent of patients with colorectal cancer. It believes its test could identify and prioritize patients for colonoscopies based on their risk for colon cancer.

"PDI has a number of diagnostic tests that are nearing final validation stages of research, and CML brings critical skills in commercialization and processing of high volume laboratory tests," Phenomenome CFO and COO John Hyshka said in a statement.

The firm plans next month to present data at the Digestive Disease Week meeting from a multi-site, 6,000-patient clinical study evaluating the performance of its colorectal cancer test.

Financial and other terms of the alliance with CML were not disclosed.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.